{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T07:25:13Z","timestamp":1792135513340,"version":"4.4.0"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplant Immunology"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.trim.2024.102168","type":"journal-article","created":{"date-parts":[[2024,12,22]],"date-time":"2024-12-22T00:42:51Z","timestamp":1734828171000},"page":"102168","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["High seroprevalence of CMV among Algerian hemodialysis patients and the general population: Intermediate-risk patients for post-transplant CMV infection"],"prefix":"10.1016","volume":"88","author":[{"given":"Lydia","family":"Lamara Mahammed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zineb","family":"Omrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nourhene","family":"Bellachia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilya Meriem","family":"Berkani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Messaoud","family":"Saidani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reda","family":"Djidjik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.trim.2024.102168_bb0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-0716-1111-1_1","article-title":"Overview of human cytomegalovirus pathogenesis","volume":"2244","author":"Fulkerson","year":"2021","journal-title":"Methods Mol Biol Clifton NJ."},{"issue":"12","key":"10.1016\/j.trim.2024.102168_bb0010","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/s41579-021-00582-z","article-title":"Pathogenesis of human cytomegalovirus in the immunocompromised host","volume":"19","author":"Griffiths","year":"2021","journal-title":"Nat Rev Microbiol."},{"issue":"2 Suppl","key":"10.1016\/j.trim.2024.102168_bb0015","article-title":"The natural course of cytomegalovirus infection and disease in renal transplant recipients","volume":"82","author":"Hartmann","year":"2006","journal-title":"Transplantation"},{"key":"10.1016\/j.trim.2024.102168_bb0020","series-title":"Core Concepts in Parenchymal Kidney Disease","first-page":"229","article-title":"Cytomegalovirus, BK, and Other Viral Infections of the Kidney","author":"Cummins","year":"2014"},{"key":"10.1016\/j.trim.2024.102168_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.trim.2022.101677","article-title":"Risk factors for cytomegalovirus infection and disease after kidney transplantation: a meta-analysis","volume":"74","author":"Tang","year":"2022","journal-title":"Transpl. Immunol."},{"issue":"6","key":"10.1016\/j.trim.2024.102168_bb0030","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1097\/TP.0000000000002191","article-title":"The third international consensus guidelines on the Management of Cytomegalovirus in solid-organ transplantation","volume":"102","author":"Kotton","year":"2018","journal-title":"Transplantation"},{"issue":"3","key":"10.1016\/j.trim.2024.102168_bb0035","doi-asserted-by":"crossref","first-page":"e2034","DOI":"10.1002\/rmv.2034","article-title":"Estimation of the worldwide seroprevalence of cytomegalovirus: A systematic review and meta-analysis","volume":"29","author":"Zuhair","year":"2019","journal-title":"Rev. Med. Virol."},{"key":"10.1016\/j.trim.2024.102168_bb0040","doi-asserted-by":"crossref","first-page":"101587","DOI":"10.1016\/j.trim.2022.101587","article-title":"Seroprevalence of cytomegalovirus antibodies and primary infection among hemodialysis patients: a systematic and meta-analysis review","volume":"72","author":"Mesgar Saravi","year":"2022","journal-title":"Transpl. Immunol."},{"issue":"6","key":"10.1016\/j.trim.2024.102168_bb0045","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/s41581-022-00542-7","article-title":"Epidemiology of haemodialysis outcomes","volume":"18","author":"Bello","year":"2022","journal-title":"Nat. Rev. Nephrol."},{"issue":"1","key":"10.1016\/j.trim.2024.102168_bb0050","doi-asserted-by":"crossref","first-page":"5041","DOI":"10.1038\/s41598-019-41619-x","article-title":"The influence of a single hemodialysis procedure on human T lymphocytes","volume":"9","author":"Lisowska","year":"2019","journal-title":"Sci. Rep."},{"issue":"13","key":"10.1016\/j.trim.2024.102168_bb0055","doi-asserted-by":"crossref","first-page":"3759","DOI":"10.3390\/jcm11133759","article-title":"Immune system dysfunction and inflammation in hemodialysis patients: two sides of the same coin","volume":"11","author":"Campo","year":"2022","journal-title":"J. Clin. Med."},{"issue":"3","key":"10.1016\/j.trim.2024.102168_bb0060","first-page":"488","article-title":"Seroprevalence of antibodies to cytomegalovirus (IgM\/IgG) among hemodialysis patients in Ibn Rochd university hospital, Casablanca (Morocco)","volume":"16","author":"Elmoumou","year":"2016","journal-title":"Int. J. Innov. Appl. Stud."},{"issue":"01","key":"10.1016\/j.trim.2024.102168_bb0065","first-page":"5","article-title":"Screening donated blood for transfusion-transmissible cytomegalovirus infection among Libyans","volume":"08","author":"Bleiblo","year":"2020","journal-title":"J. Biosci. Med."},{"issue":"3","key":"10.1016\/j.trim.2024.102168_bb0070","first-page":"155","article-title":"Seroprevalence of cytomegalovirus antibodies in Haemodialysis patients","volume":"36","author":"Ocak","year":"2006","journal-title":"Turk. J. Med. Sci."},{"issue":"2","key":"10.1016\/j.trim.2024.102168_bb0075","doi-asserted-by":"crossref","first-page":"95","DOI":"10.4103\/0971-4065.139488","article-title":"Prevalence and dynamics of cytomegalovirus infection among patients undergoing chronic hemodialysis","volume":"25","author":"Vilibic-Cavlek","year":"2015","journal-title":"Indian J Nephrol."},{"issue":"2","key":"10.1016\/j.trim.2024.102168_bb0080","first-page":"255","article-title":"Herpes group viruses: a Seroprevalence study in hemodialysis patients","volume":"56","author":"Vilibi\u0107-\u010cavlek","year":"2017","journal-title":"Acta Clin. Croat."},{"issue":"5","key":"10.1016\/j.trim.2024.102168_bb0085","article-title":"Seroprevalence for human cytomegalovirus in samples from dialysis and kidney transplanted patients","volume":"15","author":"Okubo","year":"2014","journal-title":"Rev Rede Enferm Nordeste."},{"key":"10.1016\/j.trim.2024.102168_bb0090","first-page":"19","article-title":"Seroprevalence of cytomegalovirus antibodies among hemodialysis patients in Gezira state, Central Sudan","volume":"4990","author":"Alla","year":"2015","journal-title":"World J. Pharm. Res."},{"issue":"1","key":"10.1016\/j.trim.2024.102168_bb0095","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s12865-017-0194-z","article-title":"Validation of T-track\u00ae CMV to assess the functionality of cytomegalovirus-reactive cell-mediated immunity in hemodialysis patients","volume":"18","author":"Banas","year":"2017","journal-title":"BMC Immunol."},{"issue":"1","key":"10.1016\/j.trim.2024.102168_bb0100","first-page":"8","article-title":"Seroprevalence of cytomegalovirus among hemodialysis patients in Misurata City-Libya","volume":"15","author":"AL Embaqqa","year":"2020","journal-title":"J. Med. Sci."},{"issue":"6","key":"10.1016\/j.trim.2024.102168_bb0105","first-page":"192","article-title":"Seroprevalence of cytomegalovirus in chronic hemodialysis patients in Morocco","volume":"6","author":"Ghita","year":"2021","journal-title":"Saudi. J. Pathol. Microbiol."},{"issue":"199","key":"10.1016\/j.trim.2024.102168_bb0110","first-page":"179","article-title":"Epidemiology of cytomegalovirus among patients undergoing hemodialysis in sari, Iran 2017-2018","volume":"31","author":"Aghajanian","year":"2021","journal-title":"J Mazandaran Univ Med Sci."},{"issue":"1","key":"10.1016\/j.trim.2024.102168_bb0115","first-page":"269","article-title":"Al-saqqa AR, et al prevalence and risk factors of cytomegalovirus infection among Haemodialysis patients in southern Gaza strip, Palestine. Glob","volume":"3","author":"Elottol","year":"2021","journal-title":"J. Public Health Med."},{"issue":"2","key":"10.1016\/j.trim.2024.102168_bb0120","doi-asserted-by":"crossref","first-page":"851","DOI":"10.22207\/JPAM.16.2.03","article-title":"Seroprevalence of Cytomegalovirus in Haemodialysis Patients","volume":"16","author":"Jalil","year":"2022","journal-title":"J Pure Appl Microbiol"},{"issue":"8","key":"10.1016\/j.trim.2024.102168_bb0125","article-title":"Detection of cytomegalovirus antibodies in the serum of hemodialysis patients","volume":"68","author":"Ibrahim","year":"2022","journal-title":"Clin. Lab."},{"issue":"11","key":"10.1016\/j.trim.2024.102168_bb0130","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1128\/CVI.00203-06","article-title":"National serosurvey of cytomegalovirus in Australia","volume":"13","author":"Seale","year":"2006","journal-title":"Clin. Vaccine Immunol. CVI"},{"issue":"4","key":"10.1016\/j.trim.2024.102168_bb0135","first-page":"545","article-title":"Investigation of cytomegalovirus seroepidemiology in Antalya with a population-based cross-sectional study and review of related data in Turkey","volume":"41","author":"Ataman","year":"2007","journal-title":"Mikrobiyol. Bul."},{"issue":"8","key":"10.1016\/j.trim.2024.102168_bb0140","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/1471-2334-8-111","article-title":"Seroprevalence of HHV-8, CMV, and EBV among the general population in Ghana, West Africa","volume":"18","author":"Adjei","year":"2008","journal-title":"BMC Infect. Dis."},{"issue":"12 Suppl","key":"10.1016\/j.trim.2024.102168_bb0145","first-page":"S58","article-title":"Prevalence of cytomegalovirus antibodies in blood donors at the National Blood Transfusion Centre","volume":"86","author":"Njeru","year":"2009","journal-title":"Nairobi. East Afr Med J. d\u00e9c"},{"issue":"4","key":"10.1016\/j.trim.2024.102168_bb0150","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1590\/S0037-86822010000400004","article-title":"Seroprevalence of cytomegalovirus antibodies in blood donors in southern","volume":"43","author":"Souza","year":"2010","journal-title":"Brazil. Rev. Soc. Bras Med. Trop."},{"issue":"4","key":"10.1016\/j.trim.2024.102168_bb0155","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/j.transproceed.2011.03.067","article-title":"Cytomegalovirus seroprevalence among solid organ donors in Hungary: correlations with age, gender, and blood group","volume":"43","author":"Varga","year":"2011","journal-title":"Transplant. Proc."},{"issue":"10","key":"10.1016\/j.trim.2024.102168_bb0160","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1111\/trf.12390","article-title":"Cytomegalovirus (CMV) seroprevalence in Japanese blood donors and high detection frequency of CMV DNA in elderly donors","volume":"53","author":"Furui","year":"2013","journal-title":"Transfusion (Paris)"},{"issue":"2","key":"10.1016\/j.trim.2024.102168_bb0165","first-page":"139","article-title":"Demography and seroprevalence of cytomegalovirus infection in blood donors in Mashhad in 2009","volume":"10","author":"Safabakhsh","year":"2014","journal-title":"J. Am. Sci."},{"key":"10.1016\/j.trim.2024.102168_bb0170","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jcv.2014.11.033","article-title":"Cytomegalovirus infection in the Netherlands: seroprevalence, risk factors, and implications","volume":"63","author":"Korndewal","year":"2015","journal-title":"J Clin Virol Off Publ Pan Am Soc Clin Virol"},{"issue":"4","key":"10.1016\/j.trim.2024.102168_bb0175","first-page":"171","article-title":"Sero-prevalence of human cytomegalovirus among blood donors in Lahore, Pakistan","volume":"2","author":"Rizvi","year":"2015","journal-title":"Adv. Life Sci."},{"key":"10.1016\/j.trim.2024.102168_bb0180","series-title":"Seroprevalence of Cytomegalovirus among Blood Donors at Omdurman Teaching Hospital, Omdurman, Sudan","first-page":"3","author":"Ibrahim","year":"2015"},{"issue":"6","key":"10.1016\/j.trim.2024.102168_bb0185","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000002735","article-title":"Cytomegalovirus infection in Ireland: Seroprevalence, HLA class I alleles, and implications","volume":"95","author":"Hassan","year":"2016","journal-title":"Medicine (Baltimore)"},{"issue":"0","key":"10.1016\/j.trim.2024.102168_bb0190","first-page":"187","article-title":"Cytomegalovirus seroprevalence in organ donors and kidney transplant recipients, Colombia, 2010-2014","volume":"36","author":"Arias-Murillo","year":"2016","journal-title":"Biomed Rev Inst Nac Salud."},{"issue":"7","key":"10.1016\/j.trim.2024.102168_bb0195","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1017\/S0950268817000103","article-title":"Seroprevalence of cytomegalovirus infection in France in 2010","volume":"145","author":"Antona","year":"2017","journal-title":"Epidemiol Infect. mai"},{"issue":"3\u20134","key":"10.1016\/j.trim.2024.102168_bb0200","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s00508-016-1069-7","article-title":"Seroepidemiology of cytomegalovirus infections in Croatia","volume":"129","author":"Vilibic-Cavlek","year":"2017","journal-title":"Wien. Klin. Wochenschr."},{"key":"10.1016\/j.trim.2024.102168_bb0205","first-page":"016","article-title":"Seroprevalence of cytomegalovirus among healthy blood donors in Sana\u2019a City, Yemen","volume":"3","author":"Al-Sabri","year":"2017","journal-title":"J Infect Non Infect Dis."},{"issue":"3","key":"10.1016\/j.trim.2024.102168_bb0210","doi-asserted-by":"crossref","first-page":"123","DOI":"10.14776\/piv.2018.25.e8","article-title":"Changes in cytomegalovirus Seroprevalence in Korea for 21 years: a single center study","volume":"25","author":"Choi","year":"2018","journal-title":"Pediatr. Infect Vacci."},{"issue":"2","key":"10.1016\/j.trim.2024.102168_bb0215","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/voxs.12476","article-title":"Magnitude and risk factors for cytomegalovirus infection among voluntary blood donors at National Blood Bank","volume":"14","author":"Teka","year":"2018","journal-title":"Addis Ababa Ethiopia. ISBT Sci Ser."},{"key":"10.1016\/j.trim.2024.102168_bb0220","doi-asserted-by":"crossref","DOI":"10.1017\/S0950268819000487","article-title":"The seroprevalence of cytomegalovirus infection in Belgium anno 2002 and 2006: a comparative analysis with hepatitis a virus seroprevalence","volume":"147","author":"Smit","year":"2019","journal-title":"Epidemiol. Infect."},{"issue":"Suppl. 1","key":"10.1016\/j.trim.2024.102168_bb0225","first-page":"6","article-title":"Blood donor safety, prevalence and associated factors for cytomegalovirus infection among blood donors in Minna-Nigeria, 2014","volume":"32","author":"Bawa","year":"2019","journal-title":"Pan Afr. Med. J."},{"issue":"3","key":"10.1016\/j.trim.2024.102168_bb0230","article-title":"Seroprevalence of cytomegalovirus among voluntary blood donors in Erbil Province, North Iraq","volume":"31","author":"Nanakaly","year":"2019","journal-title":"Zanco J Pure Appl Sci."},{"key":"10.1016\/j.trim.2024.102168_bb0235","doi-asserted-by":"crossref","unstructured":"Mabilangan C, Burton C, O'Brien S, Plitt S, Eurich D, Preiksaitis J. Using blood donors and solid organ transplant donors and recipients to estimate the seroprevalence of cytomegalovirus and Epstein\u2013Barr virus in Canada: A cross-sectional study. J. Assoc. Med. Microbiol Infect Dis Can. 2020;5(3):158.","DOI":"10.3138\/jammi-2020-0005"},{"issue":"6","key":"10.1016\/j.trim.2024.102168_bb0240","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1007\/s10096-020-03814-x","article-title":"Thirty years of CMV seroprevalence\u2014a longitudinal analysis in a German university hospital","volume":"39","author":"Hoehl","year":"2020","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"issue":"1","key":"10.1016\/j.trim.2024.102168_bb0245","article-title":"Seroprevalence of cytomegalovirus among blood donor in transfusion medicine: study from Bangladesh","volume":"5","author":"Shaheen","year":"2020","journal-title":"Int. J. Innov. Res. Med. Sci."},{"issue":"1","key":"10.1016\/j.trim.2024.102168_bb0250","doi-asserted-by":"crossref","first-page":"15809","DOI":"10.1038\/s41598-020-72808-8","article-title":"Metagenomic analysis and identification of emerging pathogens in blood from healthy donors","volume":"10","author":"Xu","year":"2020","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.trim.2024.102168_bb0255","doi-asserted-by":"crossref","first-page":"113","DOI":"10.4103\/ajts.AJTS_1_19","article-title":"Seroprevalence of cytomegalovirus among blood donors at a tertiary care hospital in Puducherry, India. Is testing donated blood for cytomegalovirus a viable option? Asian","volume":"15","author":"Cherukat","year":"2021","journal-title":"J. Transfus Sci."},{"issue":"2","key":"10.1016\/j.trim.2024.102168_bb0260","doi-asserted-by":"crossref","first-page":"203","DOI":"10.4103\/azmj.azmj_3_22","article-title":"Seroprevelance of cytomegalovirus in healthy blood donors in Kafr El sheikh general hospital","volume":"20","author":"El Mallah","year":"2022","journal-title":"Al-Azhar Assiut Med J."},{"issue":"2","key":"10.1016\/j.trim.2024.102168_bb0265","article-title":"Human cytomegalovirus Seroprevalence among blood donors in the Madinah region, Saudi Arabia","volume":"14","author":"Mahallawi","year":"2022","journal-title":"Cureus. f\u00e9vr"},{"issue":"1","key":"10.1016\/j.trim.2024.102168_bb0270","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1186\/s12889-022-13971-7","article-title":"A systematic literature review of the global seroprevalence of cytomegalovirus: possible implications for treatment, screening, and vaccine development","volume":"22","author":"Fowler","year":"2022","journal-title":"BMC Public Health"},{"issue":"7","key":"10.1016\/j.trim.2024.102168_bb0275","doi-asserted-by":"crossref","first-page":"515","DOI":"10.6061\/clinics\/2015(07)09","article-title":"Cytomegalovirus infection in transplant recipients","volume":"70","author":"Azevedo","year":"2015","journal-title":"Clinics"},{"issue":"4","key":"10.1016\/j.trim.2024.102168_bb0280","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1111\/ajt.14208","article-title":"Infection in organ transplantation","volume":"17","author":"Fishman","year":"2017","journal-title":"Am. J. Transplant. Off. J. Am. Soc. Transplant. Am. Soc. Transplant Surg."},{"issue":"9","key":"10.1016\/j.trim.2024.102168_bb0285","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1111\/j.1600-6143.2006.01413.x","article-title":"Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients","volume":"6","author":"Khoury","year":"2006","journal-title":"Am. J. Transplant. Off. J. Am. Soc. Transplant. Am. Soc. Transplant Surg."},{"issue":"5","key":"10.1016\/j.trim.2024.102168_bb0290","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1111\/j.1600-6143.2007.02133.x","article-title":"Improvement in long-term renal graft survival due to CMV prophylaxis with oral ganciclovir: results of a randomized clinical trial","volume":"8","author":"Kliem","year":"2008","journal-title":"Am. J. Transplant. Off. J. Am. Soc. Transplant. Am. Soc. Transplant Surg."},{"issue":"9","key":"10.1016\/j.trim.2024.102168_bb0295","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1681\/ASN.2012010100","article-title":"Long-term outcomes of pre-emptive valganciclovir compared with valacyclovir prophylaxis for prevention of cytomegalovirus in renal transplantation","volume":"23","author":"Reischig","year":"2012","journal-title":"J. Am. Soc. Nephrol. JASN"},{"issue":"5","key":"10.1016\/j.trim.2024.102168_bb0300","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1097\/TP.0000000000002024","article-title":"Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: long-term results after 7 years of a randomized clinical trial","volume":"102","author":"Witzke","year":"2018","journal-title":"Transplantation"},{"issue":"6","key":"10.1016\/j.trim.2024.102168_bb0305","article-title":"Predictors of CMV infection in CMV-seropositive kidney transplant recipients: impact of Pretransplant CMV-specific humoral immunity. Open forum","volume":"8","author":"Kirisri","year":"2021","journal-title":"Infect. Dis. Ther."}],"container-title":["Transplant Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0966327424001849?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0966327424001849?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T04:59:34Z","timestamp":1740459574000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0966327424001849"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":61,"alternative-id":["S0966327424001849"],"URL":"https:\/\/doi.org\/10.1016\/j.trim.2024.102168","relation":{},"ISSN":["0966-3274"],"issn-type":[{"value":"0966-3274","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"High seroprevalence of CMV among Algerian hemodialysis patients and the general population: Intermediate-risk patients for post-transplant CMV infection","name":"articletitle","label":"Article Title"},{"value":"Transplant Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trim.2024.102168","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102168"}}